Related Experiment Video
Updated: May 27, 2025
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
Xiaoying Tang1, Zhenyu Liu1, Liangdong Song1
1Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background:
There are discrepancies between the results of different studies regarding the prognostic role of circulating Chromogranin A (CgA) in prostate cancer. Therefore, we conducted a meta-analysis of the available findings to explore the value of circulating Chromogranin A in the prognosis of prostate cancer.
Methods:
We systematically searched the PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials databases for studies on the relationship between CgA and survival outcomes in prostate cancer from inception until December 2024, and we focused on articles detecting circulating CgA, with the primary endpoints of the studies being overall survival (OS), and progression-free survival (PFS).
Results:
Of the 2049 articles retrieved, 10 articles met our inclusion criteria, involving a total of 1445 patients. Elevated circulating CgA was associated with poorer OS (HR=1.82, 95% CI: 1.38-2.41; p<0.001) and PFS (HR=2.04, 95% CI: 1.42-2.94; p<0.001). However, no correlation was found between post-treatment circulating CgA changes and OS (HR=0.95, 95% CI: 0.66-1.37; p=0.767).
Conclusion:
Circulating CgA is a predictive marker of poor survival outcomes in prostate cancer However, the sample size of the current study is small and larger studies are needed to further validate this in the future.
